Cagrilintide 10 mg

Dragon Pharma Cagrilintide

Cagrilintide 10 mg offers researchers a potent, long-acting dual agonist targeting the amylin and calcitonin receptors (AMYR). As a novel, next-generation peptide analog of human amylin, Cagrilintide is engineered with a unique structure that dramatically extends its half-life while enhancing receptor binding affinity. Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells, playing a crucial role in regulating appetite, gastric emptying, and overall energy balance. Cagrilintide's research profile suggests it powerfully activates these pathways, leading to profound reductions in food intake and sustained weight loss in preclinical models, making it a compelling subject for metabolic and obesity research.

For bodybuilders and fitness researchers in the USA, Dragon Pharma Cagrilintide 10 mg presents a sophisticated tool for studying extreme fat loss and appetite control during contest preparation or aggressive cutting phases. Unlike traditional stimulant-based appetite suppressants, Cagrilintide works through physiological satiety signaling, promoting a natural feeling of fullness and reducing cravings without central nervous system stimulation. Its weekly or bi-weekly dosing protocol in research, enabled by its extended half-life, offers significant convenience. Manufactured under Dragon Pharma's stringent quality control in certified European facilities, this 10 mg lyophilized powder vial provides a high-purity, precisely dosed research compound for investigating long-term metabolic modulation and body composition changes.

Key Benefits:

• Potent Appetite Suppression: Activates amylin receptors in the brain to powerfully reduce hunger and promote satiety, supporting severe caloric restriction studies.
• Extended Duration of Action: Engineered for a long half-life (approximately 7 days), enabling convenient once-weekly or bi-weekly research dosing protocols.
• Dual Receptor Agonism: Binds to both amylin and calcitonin receptors (AMYR), potentially offering synergistic metabolic benefits beyond simple appetite control.
• Non-Stimulant Mechanism: Works via hormonal signaling pathways, avoiding the side effects associated with stimulant-based fat burners like anxiety or tachycardia.
• High-Potency Research Grade: 10 mg per vial provides a concentrated dose suitable for extended research cycles and precise titration in metabolic studies.

Each 2 mL vial contains 10 mg of highly pure Cagrilintide Acetate as a sterile lyophilized powder, synthesized and purified using advanced pharmaceutical techniques in Dragon Pharma's state-of-the-art research laboratories.

Product Specifications

Usage Guidelines

Research Compound Notice: The following is based on published clinical and preclinical data for educational context. Dragon Pharma Cagrilintide 10 mg is sold exclusively as a research chemical for laboratory use, not for human consumption.

In research settings, Cagrilintide is reconstituted with bacteriostatic water. Its extremely long half-life allows for once-weekly administration in most study designs, simplifying protocols compared to daily peptides. Research typically starts with a lower equivalent dose to assess tolerance in models before escalation. Due to its potent anorectic effects, studies are designed with careful monitoring of body weight, food intake, and potential body composition changes. Subcutaneous administration is standard in preclinical research.

• Standard Metabolic Research Cycle (12-16 weeks): Long-duration studies are standard to evaluate sustained weight loss, changes in fat mass, and metabolic parameter shifts with weekly dosing.
• Combination Therapy Research (16+ weeks): Often studied alongside other weight management agents (e.g., GLP-1 agonists) for potential synergistic effects in complex obesity models.

Post Cycle Therapy (PCT):

As a non-hormonal peptide, Cagrilintide does not require SERM-based PCT like Nolvadex. The primary research consideration is managing rebound appetite and metabolic adaptation after cessation. Studies might incorporate gradual tapering of the dose. To support metabolic health post-research, compounds like Sermorelin (to support natural GH pulsatility) or MK-677 (for appetite and sleep regulation in a research context) could be explored in follow-up protocols.

Supportive Research & Synergy:

Cagrilintide is a prime candidate for combination research. It is frequently studied with GLP-1 agonists like Semaglutide for enhanced weight loss efficacy. For body composition studies focused on preserving muscle during extreme cuts, adding a mild anabolic like Anavar (Oxandrolone) could be a research model. To support overall wellness during weight loss studies, incorporating a mitochondrial protector like SS-31 may be relevant.

Third-Party Lab Tested

2024-09-13

View Result

9.39 mg

Analysis Note: The September 2024 third-party HPLC test shows 9.39 mg of peptide per vial (93.9% of the 10 mg label claim), confirming high purity and accurate manufacturing. The slight variance is within acceptable industry standards for lyophilized peptides and demonstrates Dragon Pharma's commitment to transparency.

Storage Instructions

Maintaining the integrity of this long-acting peptide is paramount for research validity.

• Unreconstituted Powder: For maximum long-term stability, store the unopened vial in a freezer at -20°C (-4°F) or colder. In this lyophilized state, Cagrilintide remains stable for at least 24 months. Avoid temperature fluctuations and protect from light.
• After Reconstitution: Once reconstituted with bacteriostatic water, the solution must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Due to its albumin-binding properties and stability, the reconstituted solution may remain viable for research for 4-6 weeks when refrigerated, but best practice is to use it within 30 days. Do not freeze the liquid solution.
• Handling: Use strict aseptic technique during reconstitution to prevent bacterial contamination, which is critical for weekly dosing protocols. Keep vials upright and clearly labeled.